DRUG NAME: Lisinopril

---

Therapeutic Class:

---

Subclass:

---

Schedule (India):

---

Route(s)

• Injectable (IV/IM/SC): No parenteral formulation of lisinopril exists anywhere globally. Lisinopril is a hydrophilic compound formulated exclusively for oral administration. When intravenous ACE inhibition is required (e.g., hypertensive emergency in a patient unable to swallow, or perioperative BP control), enalaprilat — the only IV ACEi — is the appropriate agent.
• Sublingual: Not recommended. No pharmacokinetic or clinical data support sublingual administration of lisinopril tablets. Lisinopril absorption is mediated by the intestinal peptide transporter PEPT1, which is located in the small intestinal epithelium — sublingual placement does not bypass the low oral bioavailability (~25%), nor does it offer a meaningful onset advantage.
• Rectal/Nasogastric: No formal rectal absorption data. Tablets may be crushed and administered via nasogastric tube (see Reconstitution/Administration section in Part 2), though bioavailability by this route has not been formally studied.

---

Biosimilar Status:

---

Formulations Available in India

Single-ingredient tablets:

---

Fixed-Dose Combinations (FDCs) available in India:

• Titrating lisinopril to heart failure target doses (20–40 mg) where HCTZ may not be co-indicated
• Adjusting diuretic dose for fluid status while maintaining ACEi dose for cardio-renal protection
• HCTZ is ineffective at eGFR <30 mL/min (lisinopril may still be continued with dose adjustment)

---

PHARMACOKINETICS

---

---

• ACE inhibition by lisinopril is concentration-dependent up to the point of maximal tissue ACE occupancy, after which further dose increases produce diminishing additional ACE inhibition.
• The pharmacodynamic effect (BP lowering, neurohormonal modulation) outlasts the plasma half-life because of prolonged, high-affinity binding to tissue ACE with slow dissociation kinetics. This allows effective once-daily dosing despite a plasma t½ of only ~12 hours.
• The true pharmacological target is tissue ACE (in vasculature, heart, kidney, adrenal glands), not circulating plasma ACE. Plasma ACE activity is used as a measurable surrogate but does not perfectly correlate with tissue ACE inhibition.
• Steady state is reached within 2–3 days of once-daily dosing at a constant dose.

---

---

---

---

Clinical implications:

---

1. Indication-specific evidence — ramipril has the strongest high-CV-risk evidence (HOPE trial); perindopril for stable CAD (EUROPA trial); lisinopril for post-MI (GISSI-3) and HF dose-titration (ATLAS)
2. Patient-specific factors — hepatic function (favours lisinopril), drug interaction risk (favours lisinopril), cost, adherence preference for OD dosing
3. Availability and cost in India — enalapril and ramipril are NLEM-listed and therefore generally less expensive; lisinopril is widely available but non-NLEM

---

ADULT INDICATIONS + DOSING  

---

---

Step-up algorithm positioning:

Combinations to AVOID:

---

Mandatory baseline investigations (all indications):

Post-initiation monitoring (all indications):

• Recheck serum creatinine and potassium within 1–2 weeks of starting lisinopril and within 1–2 weeks of every dose increase
• A creatinine rise of ≤30% from baseline is expected and acceptable — reflects reduced glomerular hyperfiltration and is haemodynamic, not nephrotoxic
• If creatinine rises >30% or potassium rises to ≥5.5 mEq/L → reduce dose or discontinue; investigate for renal artery stenosis, NSAID use, or concurrent potassium-raising drugs

• Angioedema risk: Incidence ~0.1–0.5% (higher in Black patients and South Asian populations). Can occur at any time during therapy, including after years of stable use. If angioedema occurs → permanently discontinue ALL ACEi. Do NOT rechallenge with any ACEi. ARB may be cautiously substituted (cross-reactivity risk <5%), preferably under specialist supervision with observed first dose.
• First-dose hypotension: Risk highest in volume-depleted, diuretic-treated, heart failure, or elderly patients. See dose modifications within each indication below.

---

Primary Indication 1: Essential Hypertension

BP Target Guidance (Antihypertensive Class-Specific):

---

Mandatory Clinical Notes — Hypertension:

• Hepatic impairment — lisinopril requires no hepatic activation (non-prodrug) and undergoes zero hepatic metabolism. In patients with cirrhosis or significant liver disease who need an ACEi, lisinopril offers the most pharmacokinetically predictable option. (See Unique Pharmacological Note in PK section, Part 1.)
• Polypharmacy / High drug interaction risk — lisinopril has no CYP enzyme involvement, no transporter-mediated interactions, and negligible protein binding, effectively eliminating pharmacokinetic drug interactions. Preferred in patients on complex regimens (anti-TB, antiretrovirals, antiepileptics, warfarin).
• Once-daily dosing — superior adherence vs captopril (TID) or enalapril (BD). Matches ramipril and perindopril in frequency.
• No food interaction — can be taken at any time, with or without food.

• vs Ramipril: Ramipril has stronger drug-specific evidence for high-CV-risk patients (HOPE trial). Ramipril is NLEM-listed. For hypertension alone without compelling indications, both are equivalent.
• vs Enalapril: Enalapril requires BD dosing (adherence disadvantage). Enalapril is NLEM-listed and often cheaper. For uncomplicated hypertension, lisinopril’s OD dosing is an advantage.
• vs Amlodipine: Different class (CCB). Amlodipine may be preferred when ankle oedema is not a concern and cough/hyperkalaemia risk is relevant. Combination of both is often preferred over either alone.
• vs ARBs (e.g., telmisartan, losartan): ACEi and ARBs provide similar BP lowering. ARBs have no cough risk (~10% of ACEi users develop cough). ACEi are generally tried first; ARBs are the standard alternative if cough occurs.

• Bilateral renal artery stenosis (or stenosis in solitary kidney) — risk of precipitous renal failure
• Known ACEi-induced angioedema (even if from a different ACEi) — absolute contraindication to ALL ACEi
• Pregnancy (confirmed or planned) — ⛔ Teratogenic in all trimesters
• Baseline K⁺ ≥5.5 mEq/L before correction
• eGFR <10 mL/min without dialysis support — extreme caution; usually switch to alternative class
• Severe aortic stenosis / hypertrophic obstructive cardiomyopathy with outflow obstruction — risk of syncope from preload reduction

• BP reduction begins within 1 hour of first dose. Peak effect at 6–8 hours.
• Steady-state BP effect achieved within 2–4 weeks of a stable dose.
• Full assessment of BP response requires at least 2 weeks at a given dose.

• If BP not at target after 2–4 weeks at maximum tolerated dose (40 mg), do not switch — add a second agent (CCB or thiazide) per step-up algorithm.
• Switch to ARB ONLY if intolerable cough develops (typically after 1–12 weeks of ACEi therapy).
• Switch ACEi class to alternative class if angioedema occurs (⛔ do not switch to another ACEi).
• Switch to alternative class if persistent hyperkalaemia (K⁺ >5.5 mEq/L) despite dietary modification and stopping potassium-raising co-medications.

• Concurrent diuretic therapy → start 5 mg (risk of first-dose hypotension from volume depletion)
• Elderly ≥60 years → start 5 mg, titrate slowly
• Renal impairment → see Renal Adjustment table (Part 3)
• Addition of potassium-sparing diuretic, potassium supplement, or SGLT2 inhibitor → recheck K⁺ within 1 week

---

Primary Indication 2: Chronic Heart Failure — Reduced Ejection Fraction (HFrEF, LVEF ≤40%), NYHA Class II–IV

Mandatory Clinical Notes — Heart Failure:

• Hepatic congestion / Congestive hepatopathy: Common in decompensated HF. Lisinopril’s non-prodrug, non-hepatic-metabolism profile is advantageous when hepatic esterase function may be impaired. (See Unique Pharmacological Note, Part 1.)
• Polypharmacy: HF patients are typically on 4–8 concurrent medications (beta-blocker, diuretic, MRA, digoxin, anticoagulant, statin). Lisinopril’s zero drug interaction profile is a practical advantage.
• Once-daily dosing: Important for adherence in patients already managing complex multi-drug regimens.

• Persistent NYHA III–IV symptoms despite maximum tolerated ACEi + beta-blocker + MRA → consider switch to sacubitril/valsartan (PARADIGM-HF).
• Intolerable cough → switch to ARB (valsartan — Val-HeFT; candesartan — CHARM-Alternative).
• Angioedema → discontinue ACEi; ARB may be cautiously substituted OR switch to ARNI with 36-hour washout.
• Recurrent symptomatic hypotension preventing uptitration → reduce diuretic first; consider lower ACEi target with addition of hydralazine + isosorbide dinitrate if African descent or ACEi-intolerant.

• Echocardiography — confirm LVEF ≤40% and assess valvular/structural disease
• NT-proBNP or BNP — baseline for future comparison (RECOMMENDED, not mandatory)
• Haemoglobin, TSH, iron studies — to exclude reversible HF causes

• Symptomatic hypotension (dizziness, lightheadedness, pre-syncope)
• Creatinine rises >30% from baseline
• K⁺ ≥5.5 mEq/L
• Intolerable adverse effects

---

Primary Indication 3: Acute Myocardial Infarction — Early Treatment (Haemodynamically Stable, Within 24 Hours of Symptom Onset)

Mandatory Clinical Notes — Acute MI:

• vs Captopril: Captopril requires TID dosing (adherence disadvantage in post-MI patients on multiple new medications). Lisinopril’s OD dosing is preferred for long-term adherence.
• vs Ramipril: Ramipril (HOPE, AIRE) has strong evidence for long-term CV risk reduction but less evidence for the ultra-early (<24 h) initiation strategy. In practice, either agent is acceptable.

---

Primary Indication 4: Diabetic Nephropathy — Type 2 Diabetes with Hypertension and Albuminuria

Mandatory Clinical Notes — Diabetic Nephropathy:

• BP target: 2–4 weeks
• Albuminuria reduction: 4–12 weeks (serial UACR monitoring). Expect 30–50% reduction in albuminuria from baseline at optimal dose.
• eGFR stabilisation / slowed decline: Assessed over 6–12 months.
• Hard renal endpoints (dialysis, doubling of creatinine): Demonstrated over years in clinical trials.

• If albuminuria does not reduce by ≥30% after 3 months at maximum tolerated dose WITH adequate BP control → consider switching to ARB (losartan, irbesartan — with dedicated renal trial evidence), or adding SGLT2 inhibitor (dapagliflozin, empagliflozin — CREDENCE, DAPA-CKD, EMPA-KIDNEY evidence) for additive renoprotection.
• If eGFR declines >30% acutely after initiation → investigate for renal artery stenosis, NSAIDs, dehydration, UTI.

• Urine albumin-creatinine ratio (UACR) — quantify baseline albuminuria
• HbA1c — assess glycaemic control
• Lipid profile — comprehensive CV risk assessment in T2DM

---

Secondary Indications — Adults Only (Off-label)

---

Secondary Indication 1: Non-Diabetic Proteinuric Chronic Kidney Disease

• Indication: CKD of any aetiology (IgA nephropathy, FSGS, membranous nephropathy, hypertensive nephrosclerosis, etc.) with proteinuria (UPCR >0.5 g/g or UACR >300 mg/g), with or without hypertension.
• Dose: Starting dose 5–10 mg OD (2.5 mg if eGFR 15–30); titrate to maximum tolerated dose (up to 40 mg OD) targeting both BP (<130/80 mmHg) and maximum proteinuria reduction.
• Duration: Indefinite, as long as proteinuria and CKD persist and drug is tolerated.
• Specialist only: Nephrology referral recommended for initial assessment and guidance; ongoing prescription may be managed in primary care.
• Label status:OFF-LABEL but accepted standard practice in India. ACEi use in proteinuric CKD is universally recommended by Indian Society of Nephrology, API Textbook, KDIGO guidelines, and ICMR chronic disease management protocols.
• Evidence basis: ACEi class effect — Jafar meta-analysis (Ann Intern Med 2001); AIPRD individual patient data meta-analysis; REIN trial (ramipril-specific, non-diabetic nephropathy). No large trial using lisinopril specifically in non-diabetic CKD, but class-effect evidence is strong.
• Level of evidence quality:Strong (multiple RCTs and meta-analyses for ACEi class; accepted standard practice despite being off-label for lisinopril specifically).

---

Secondary Indication 2: Migraine Prophylaxis

• Indication: Episodic migraine prophylaxis in adults (≥4 migraine days/month) who cannot tolerate or have contraindications to first-line prophylactic agents (propranolol, amitriptyline, flunarizine, topiramate, valproate).
• Dose: Starting dose 5 mg OD; titrate to 10–20 mg OD over 4–8 weeks.
• Duration: Minimum 3-month trial before assessing efficacy. If effective, continue for 6–12 months then reassess.
• Specialist only: Neurologist initiation preferred.
• Label status:OFF-LABEL.
• Evidence basis: Single randomised, double-blind, crossover trial (Schrader et al., BMJ 2001; n=60) — lisinopril 20 mg/day reduced migraine days by 20%, headache severity index by 20%, and days with headache by 17% compared to placebo. Modest effect. Not replicated in larger trials.
• Level of evidence quality:Moderate (single adequately-powered RCT with positive result, but limited to one trial; no Indian guideline endorsement specifically for lisinopril).
• Clinical note:NOT a first-line migraine prophylactic. Consider only when propranolol, amitriptyline, flunarizine, topiramate, and valproate are contraindicated, not tolerated, or ineffective. May be a pragmatic choice in patients with coexistent hypertension AND migraine.

---

Secondary Indication 3: Scleroderma Renal Crisis

• Indication: Scleroderma renal crisis (SRC) — medical emergency characterised by acute-onset severe hypertension, rapidly progressive renal failure, and microangiopathic haemolytic anaemia in patients with systemic sclerosis (diffuse cutaneous type).
• Dose: Aggressive uptitration required — start 5–10 mg and increase rapidly (every 12–24 hours) targeting BP normalisation. Doses up to 40 mg/day may be needed.
• Specialist only:Yes — Rheumatology and/or Nephrology mandatory.
• Label status:OFF-LABEL.
• Evidence basis: ACEi class effect. Historical evidence is strongest for captopril (Steen et al., Arthritis Rheum 1990). Lisinopril and other ACEi are used when captopril is unavailable or OD dosing is preferred. No head-to-head comparison between ACEi in SRC exists.
• Level of evidence quality:Moderate (observational studies and retrospective case series for ACEi class; no RCTs in SRC — would be unethical to withhold ACEi).
• Clinical note: ⚠️ Captopril is the historically preferred ACEi for SRC because of its short half-life (rapid dose titration, rapid offset if hypotension occurs) and the historical data. Lisinopril’s longer half-life and duration make it less ideal for the acute management phase but acceptable if captopril is not available. Once BP is controlled, long-term ACEi (including lisinopril) is continued indefinitely.

---

MISSED DOSE / DELAYED DOSE GUIDANCE

• Lisinopril does NOT cause rebound hypertension or withdrawal syndrome upon discontinuation. However, BP will return to baseline over days.
• No immunogenicity concerns (not a biologic).
• No re-titration is needed for short gaps (≤7 days) at any indication.
• For HF patients with marginal haemodynamic tolerance, longer gaps (>2 weeks) warrant cautious restarting.

---

RECONSTITUTION / ADMINISTRATION QUICK REFERENCE (For Nurses & Clinical Staff)

---

---

---

---

PAEDIATRIC DOSING (Specialist Only)

---

---

---

---

Neonatal Dosing

• ⛔ Severe, prolonged hypotension — resistant to fluids and vasopressors
• ⛔ Acute oliguric/anuric renal failure — often irreversible in preterm neonates
• ⛔ Hyperkalaemia — compounded by immature tubular potassium secretion
• ⛔ Skull ossification defects — if exposure was in utero (relevant for maternal exposure, not neonatal postnatal dosing)

• Captopril is strongly preferred over lisinopril in neonates due to its short half-life (~1.5–4 hours) and rapid offset — allowing faster reversal of adverse haemodynamic effects if hypotension occurs.
• Lisinopril’s long duration of action (~24 hours) and prolonged half-life (further prolonged in neonatal renal immaturity, potentially exceeding 40–60 hours) makes it a poor choice in neonates where rapid dose adjustability is critical for safety.
• No established neonatal dosing regimen for lisinopril exists.

---

Primary Indications — Paediatric (Approved / Standard in India)

---

Paediatric Indication 1: Hypertension in Children ≥6 Years

• Starting dose: 0.07 × 30 = 2.1 mg → round to 2 mL of 1 mg/mL suspension or use half of a 5 mg tablet (≈2.5 mg)
• Maximum dose: 0.61 × 30 = 18.3 mg → cap at 18 mg (practically, use 15 or 20 mg from available tablet strengths)

---

Mandatory Clinical Notes — Paediatric Hypertension:

• ACEi are preferred (over CCBs or beta-blockers) in children with:
  • CKD with proteinuria — renoprotective benefit
  • Diabetes with microalbuminuria — anti-proteinuric benefit
  • Left ventricular hypertrophy — regression of hypertrophy
  • Post-renal transplant hypertension — caution with calcineurin inhibitor interactions (pharmacodynamic, not PK)
• Lisinopril specifically: once-daily dosing is a major adherence advantage in children (fewer medication battles with parents/caregivers). No taste issue if swallowed as whole tablet (≥6 years can usually manage this with training).

• vs Enalapril: Enalapril requires BD dosing; enalapril oral solution is also not commercially available in India. Lisinopril’s OD dosing advantage is significant in paediatric adherence. Both are off-NLEM for paediatric use.
• vs Amlodipine: Amlodipine has a commercially available oral suspension (in some Indian markets) and extensive paediatric dosing data. Preferred when no compelling indication exists for ACEi. However, if proteinuria or LVH is present, ACEi (lisinopril) is preferred.
• vs ARBs (losartan): Losartan has specific paediatric hypertension data and a tablet formulation that can be crushed. ARB is the alternative if ACEi cough develops.

• ⛔ Age <6 years (off-label; limited data — specialist only)
• ⛔ Bilateral renal artery stenosis (rare in children; consider in fibromuscular dysplasia)
• ⛔ Known ACEi angioedema history
• ⛔ Adolescent girls of childbearing potential without reliable contraception — counsel about teratogenicity
• ⛔ Concurrent aliskiren or dual RAAS blockade

---

Secondary Indications — Paediatric (Off-label)

---

Paediatric Secondary Indication 1: Proteinuric Chronic Kidney Disease in Children (Non-Diabetic)

• Indication: CKD in children ≥6 years with significant proteinuria (UPCR >0.5 g/g) — including IgA nephropathy, focal segmental glomerulosclerosis (FSGS), post-HUS nephropathy, reflux nephropathy, and other proteinuric CKD.
• Dose:
  • Starting: 0.07 mg/kg OD (lower end if eGFR 30–60; start 0.04 mg/kg if eGFR 15–30)
  • Titrate by 0.07 mg/kg every 2–4 weeks targeting maximum tolerated dose for maximum proteinuria reduction
  • Usual maintenance: 0.3–0.6 mg/kg OD
  • Maximum: 0.61 mg/kg per dose or 40 mg per day (whichever is lower)
• Duration: Indefinite — as long as proteinuria persists and CKD is present.
• Specialist only:Yes — Paediatric nephrology mandatory.
• Label status:OFF-LABEL but accepted standard practice. KDIGO Paediatric CKD guidelines and Indian Society of Nephrology recommendations support ACEi use in proteinuric CKD in children.
• Evidence basis: Paediatric ESCAPE trial (ramipril in children with CKD — intensified BP target + ACEi slowed renal decline; Effect of Strict Blood Pressure Control and ACE Inhibition on Progression of CRF in Pediatric Patients; NEJM 2009). Class effect; no lisinopril-specific paediatric CKD trial.
• Level of evidence quality:Moderate (adult RCTs with paediatric RCT data for ramipril; class extrapolation to lisinopril).

---

Paediatric Secondary Indication 2: Heart Failure in Children

• Indication: Symptomatic heart failure in children ≥6 years with reduced systolic function (dilated cardiomyopathy, post-myocarditis, congenital heart disease with ventricular dysfunction).
• Dose:
  • Starting: 0.05–0.1 mg/kg OD
  • Titrate by 0.05–0.1 mg/kg every 1–2 weeks
  • Usual maintenance: 0.1–0.5 mg/kg OD
  • Maximum: 0.6 mg/kg per dose or 40 mg per day
• Duration: Indefinite — as long as ventricular dysfunction persists.
• Specialist only:Yes — Paediatric cardiologist mandatory.
• Label status:OFF-LABEL. ACEi use in paediatric HF is standard practice based on extrapolation from adult HF outcome trials. No paediatric HF-specific outcome RCTs exist for any ACEi.
• Evidence basis: Adult RCTs (CONSENSUS, SOLVD, ATLAS — enalapril and lisinopril) with paediatric PK extrapolation. Paediatric observational data and expert consensus support ACEi use. IAP Drug Formulary recommends ACEi for paediatric HF.
• Level of evidence quality:Moderate (adult RCTs with paediatric PK extrapolation and consensus endorsement; no paediatric-specific HF outcome trials).
• Clinical note:Enalapril has the most published paediatric HF experience. Captopril has long-standing paediatric use (especially in infants — liquid formulation easier). Lisinopril’s advantage is OD dosing in older children who can swallow tablets. For infants and children <6 years, captopril or enalapril is preferred.

---

Paediatric Secondary Indication 3: Diabetic Nephropathy in Adolescents (Type 1 or Type 2 Diabetes)

• Indication: Adolescents (≥12 years) with diabetes and persistent microalbuminuria (UACR ≥30 mg/g on at least 2 of 3 samples).
• Dose: Adult dosing applies (≥12 years, ≥40 kg): starting 5 mg OD, titrate to 10–20 mg OD.
• Duration: Indefinite.
• Specialist only: Paediatric endocrinologist / paediatric nephrologist.
• Label status:OFF-LABEL but accepted standard practice. ISPAD guidelines and RSSDI (adapted for adolescents) recommend ACEi/ARB for diabetic nephropathy in adolescents.
• Evidence basis: EUCLID trial (lisinopril in T1DM adults); extrapolation to adolescents. No paediatric-specific RCTs.
• Level of evidence quality:Moderate (adult RCTs with adolescent extrapolation; guideline endorsement).

---

RENAL ADJUSTMENT

---

---

• Prolonged and excessive hypotension
• Severe hyperkalaemia (K⁺ >6.0 mEq/L) — compounded by reduced renal potassium excretion
• AKI precipitated by excessive afterload reduction in patients with marginal renal perfusion

---

---

• There is no formulation-switching consideration in renal impairment.
• Tablet splitting (2.5 mg → ~1.25 mg half-tablet) is feasible for fine-tuning low doses in advanced CKD, though dose accuracy with manual splitting is approximate.
• Extemporaneous 1 mg/mL suspension can achieve very low doses (e.g., 1 mg, 1.5 mg) if needed.

---

• ACE inhibition efficacy depends on tissue ACE occupancy, not purely on plasma concentration. Once adequate tissue binding is achieved, further plasma level increases may not add benefit.
• However, in young ICU patients with ARC who show suboptimal BP response to standard lisinopril doses, clinicians should:
  • (a) Rule out other causes of hypertension in ICU (pain, agitation, volume overload, endocrine)
  • (b) Consider higher lisinopril doses (up to 40 mg/day)
  • © Consider switching to an ACEi NOT primarily renally cleared — fosinopril has dual hepatic + renal elimination and is less affected by ARC, though availability in India is limited
  • (d) In practice, ICU hypertension is more often managed with IV agents (labetalol, nicardipine, enalaprilat, nitroglycerine) rather than oral lisinopril

---

• ACEi → reduces efferent arteriolar tone → reduces intraglomerular pressure
• Diuretic → reduces intravascular volume → reduces renal perfusion pressure
• NSAID → inhibits prostaglandin-mediated afferent arteriolar vasodilation → reduces renal blood flow

---

HEPATIC ADJUSTMENT

---

• Lisinopril undergoes zero hepatic metabolism — it is not a prodrug, does not require hepatic activation, and is not metabolised by any hepatic enzyme (CYP or otherwise).
• Lisinopril has negligible plasma protein binding — it binds only to ACE, not to albumin. Therefore, hypoalbuminaemia (universal in decompensated cirrhosis) does not alter its free fraction or pharmacokinetics.
• It is excreted 100% unchanged by the kidneys — hepatic function plays no role in its elimination.

---

---

Specific scenarios in hepatic disease:

• ACEi may be used cautiously if systemic hypertension is confirmed (SBP consistently ≥140/90 mmHg in clinical setting, not just during acute decompensation).
• Start 2.5–5 mg OD. Titrate slowly (every 4 weeks).
• Monitor standing BP at every visit — orthostatic hypotension may be the first sign of excessive RAAS blockade.
• Monitor serum sodium (risk of worsening dilutional hyponatraemia).
• Specialist supervision (hepatologist + cardiologist/nephrologist) recommended.

• ⚠️ Avoid lisinopril (or any ACEi) in this setting unless there is a compelling indication (HFrEF, post-MI) that outweighs the risk.
• If used: start at the lowest dose (2.5 mg OD), recheck creatinine, potassium, and sodium within 3–5 days. Discontinue if SBP <90, K⁺ >5.5, or Na⁺ <125 mEq/L.

• This is NOT intrinsic liver disease — hepatic esterase function is generally preserved.
• However, lisinopril’s non-prodrug profile is still advantageous because hepatic blood flow may be reduced in severe right heart failure, potentially delaying prodrug activation of other ACEi.
• Standard HFrEF dosing applies.

---

---

CONTRAINDICATIONS

---

Allergy Cross-Reactivity — ACE Inhibitors:

---

CAUTIONS

---

⚠️ High-Priority Cautions

---

Standard Cautions

---

• No tapering schedule is required for discontinuation.
• Lisinopril can be stopped abruptly if needed (e.g., angioedema, pregnancy, severe hypotension).
• However, in patients with HFrEF, abrupt cessation may lead to haemodynamic deterioration (increased afterload, fluid retention) over days to weeks — replacement with an ARB or alternative neurohormonal agent is recommended rather than simply stopping.

---

PREGNANCY

Trimester-specific risks:

• If a woman on lisinopril becomes pregnant: Discontinue immediately upon confirmation of pregnancy. Switch to methyldopa or labetalol.
• If first-trimester exposure has already occurred: Counsel about potential (but uncertain) teratogenic risk. Offer detailed fetal anatomical ultrasound at 18–20 weeks (targeted cardiac assessment). Do NOT recommend termination based solely on first-trimester ACEi exposure — the absolute risk increase is small and data is observational.
• If second/third-trimester exposure has occurred: Urgent obstetric referral. Serial ultrasound for amniotic fluid volume, fetal renal function (bladder visualisation), skull ossification, growth. Neonatology alert for postnatal renal function and BP monitoring.

• All women of childbearing potential prescribed lisinopril must be counselled that ACEi are contraindicated in pregnancy.
• Ideally, switch to a pregnancy-safe antihypertensive (methyldopa, labetalol, nifedipine) before planned conception.
• If unplanned pregnancy occurs, stop lisinopril immediately and contact prescriber. Do not wait for the next scheduled appointment.
• Document counselling in medical records.

• Female fertility: No known direct effect on female fertility.
• Male fertility: No known effect on spermatogenesis, sperm quality, or male fertility. No washout period required before planned conception in male patients.

---

LACTATION

---

ELDERLY

---

---

---

---

Beers Criteria / STOPP-START relevance:

• Beers Criteria (AGS 2023): ACE inhibitors are NOT listed as potentially inappropriate in elderly (they are generally considered appropriate). The Beers list is NOT a primary Indian reference — frame as additional context only.
• STOPP-START Criteria: ACEi are a START criterion (i.e., should be STARTED) in elderly patients with HFrEF, post-MI with systolic dysfunction, or diabetic nephropathy — indicating under-prescribing is the more common error in elderly. STOPP criterion: Lisinopril should be STOPPED if persistent hyperkalaemia (K⁺ >5.5), persistent AKI, or bilateral RAS is identified.

---

---

• Tapering: No tapering required — lisinopril can be stopped abruptly. No withdrawal syndrome.
• Expected effects of stopping: BP will rise to pre-treatment levels over days. In HF patients: potential for fluid retention and decompensation over weeks.

---

• Recommended for all elderly hypertensive patients on lisinopril.
• Target home BP: <135/85 mmHg (home values are typically 5 mmHg lower than clinic values).
• Practical guidance:
  • Use a validated, automatic, upper-arm cuff device (not wrist monitors)
  • Measure after 5 minutes of seated rest, before taking morning medication
  • Record 2 readings, 1 minute apart, on at least 4 days per week
  • Bring the BP diary to every clinic visit
  • Report any reading >180/110 or <90/60 immediately

---

MAJOR DRUG INTERACTIONS

---

MODERATE DRUG INTERACTIONS

---

COMMON ADVERSE EFFECTS

---

SERIOUS ADVERSE EFFECTS

---

---

• ⛔ NEVER re-challenge with ANY ACEi — recurrence risk is very high and severity may be worse.
• ARB cautious substitution: ~95–98% of patients who had ACEi angioedema can tolerate ARBs safely. However, ~2–5% cross-reactivity exists. If ARB is necessary (compelling indication — HFrEF, diabetic nephropathy): administer first dose under observation (clinic or hospital setting, 4-hour observation). Counsel patient on angioedema symptoms and action plan. Consider sacubitril/valsartan with extreme caution only (see Contraindication #7 and Major Interaction #2).

---

---

LABORATORY TEST INTERFERENCE

---

MONITORING REQUIREMENTS

---

---

---

---

Therapeutic Drug Monitoring (TDM): Not applicable. Lisinopril does not require serum drug level monitoring. There is no established therapeutic range for plasma lisinopril concentration. Dose is titrated to clinical response (BP, proteinuria reduction, HF symptoms), not to drug levels.

---

PATIENT COUNSELLING

---

---

• Take one tablet, once a day, at the same time each day.
• You can take it with food or without food — it does not matter.
• Swallow the tablet whole with a glass of water.
• If you cannot swallow the tablet, it can be crushed and mixed with a spoonful of water, curd, or soft food.
• Your doctor may start with a low dose and slowly increase it over weeks. Take only the dose your doctor has prescribed.

---

• If you remember within 12 hours → take the missed tablet right away, then take your next tablet at the usual time tomorrow.
• If more than 12 hours have passed → skip the missed tablet. Take your next tablet at the usual time tomorrow.
• Never take two tablets together to make up for a missed dose.
• If you forget for several days in a row, do not worry about catching up — just restart at your usual dose and inform your doctor at the next visit.

---

• Dry cough — this is the most common side effect. It is a dry, tickling cough, not related to a cold or infection. It is not dangerous but can be annoying. It usually goes away within 1–4 weeks after stopping the medicine. Tell your doctor if it bothers you — they can switch you to a different medicine.
• Dizziness or lightheadedness — especially when you first start the medicine or when the dose is increased. This usually improves after a few days. Get up slowly from sitting or lying down.
• Mild headache or tiredness — usually goes away within 1–2 weeks.

---

• Swelling of your face, lips, tongue, or throat — this is a rare but serious allergic reaction. It can make it difficult to breathe or swallow. This is a medical emergency.
• Difficulty breathing or swallowing
• Severe dizziness, fainting, or feeling like you might pass out
• Very little or no urine output for more than 12 hours
• Severe stomach pain (especially if sudden, with nausea/vomiting — can be a rare reaction affecting the intestines)

• Muscle weakness, cramps, or an unusual heartbeat (may suggest high potassium)
• Persistent dry cough that interferes with sleep or daily activities
• Unexpected fever, sore throat, or mouth ulcers (very rare — may suggest low blood cell count)
• Yellowing of eyes or skin (very rare — may suggest liver problem)

---

---

• Store at room temperature (below 30°C). Keep in a cool, dry place.
• ℹ️ In hot Indian summer (>40°C): Store the medicine inside the house (not on windowsills or in cars). If the room is very hot and humid, keep the medicine strip in an airtight container. A small silica gel sachet from another medicine packet can help absorb moisture.
• Do not refrigerate unless instructed.
• Keep away from children.
• Keep in the original blister packaging until use.

---

• Lisinopril is usually a lifelong medicine for blood pressure, heart failure, or kidney protection. Do NOT stop it on your own, even if you feel well — your blood pressure will rise back if you stop.
• For post–heart attack (MI) use: your doctor will tell you how long to continue based on your heart test results.
• Unlike some medicines, lisinopril is NOT habit-forming and does NOT cause withdrawal symptoms when stopped. But stopping it without your doctor’s advice can allow your blood pressure or heart condition to worsen.

---

• Your doctor will ask for blood tests (creatinine and potassium) about 1–2 weeks after starting the medicine and after each dose increase.
• Once your dose is stable: blood tests every 3–6 months.
• Bring your home BP diary to every visit if you monitor at home.
• If you have diabetes: continue your regular sugar tests — lisinopril may slightly improve your blood sugar readings.

---

---

• Help the patient take the medicine at the same time every day.
• Watch for signs of dizziness or unsteadiness — especially when getting up from bed or chair. Help them stand up slowly.
• Watch for swelling of the face, lips, or tongue — this is a rare emergency. Go to the hospital immediately.
• Check that the patient is not taking pain medicines (ibuprofen, Combiflam) bought from the chemist without asking the doctor.
• Ensure the patient is not using “low-sodium salt” (potassium-based salt substitutes).
• If the patient has heart failure: help them weigh themselves daily on a home weighing scale. Report a weight gain of >1 kg in 24 hours or >2 kg in a week to the doctor.
• If the patient has difficulty swallowing tablets: the tablet can be crushed and mixed with soft food. Discuss with the doctor.

---

---

BRANDS AVAILABLE IN INDIA

---

---

---

---

---

PRICE RANGE (INR)

---

---

---

---

---

CLINICAL PEARLS

---

---

---

---

---

---

---

VERSION

---

REFERENCES

1. CDSCO Product Insert — Listril® (Lisinopril) Tablets, Torrent Pharmaceuticals Ltd. Approved prescribing information. Accessed via CDSCO product database and manufacturer package insert (revision date: 2023).
2. CDSCO Product Insert — Zestril® (Lisinopril) Tablets, AstraZeneca. Originator brand prescribing information (Indian registration).
3. National List of Essential Medicines (NLEM) India, 2022. Ministry of Health and Family Welfare, Government of India. [Lisinopril not listed; enalapril and ramipril are listed under cardiovascular medicines.]
4. Indian Guidelines on Hypertension IV (IGH-IV), 2019. Hypertension India (Journal of the Indian Society of Hypertension). Consensus document endorsed by the Cardiological Society of India (CSI) and the Association of Physicians of India (API).
5. API Textbook of Medicine, 11th Edition. Association of Physicians of India. Chapters on: Hypertension (Chapter 7.1); Heart Failure (Chapter 6.3); Acute Coronary Syndromes (Chapter 6.2); Diabetic Nephropathy (Chapter 15.4).
6. Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 13th Edition (2018). Brunton LL, Hilal-Dandan R, Knollmann BC (eds). Chapter 26: Renin and Angiotensin (ACE inhibitors — pharmacology, pharmacokinetics, transporter involvement, PEPT1/PEPT2 uptake, mechanism of action, adverse effects). McGraw-Hill Education.
7. Harrison’s Principles of Internal Medicine, 21st Edition (2022). Jameson JL et al. (eds). Chapters on: Hypertensive Vascular Disease (Chapter 277); Heart Failure (Chapter 257); Diabetic Nephropathy (Chapter 405).
8. CSI Heart Failure Guidelines. Cardiological Society of India. Position statements on HFrEF management, ACEi/ARB/ARNI positioning, and uptitration protocols.
9. RSSDI Clinical Practice Recommendations for Management of Type 2 Diabetes Mellitus, 2019. Research Society for the Study of Diabetes in India. Sections on: Diabetic kidney disease, antihypertensive selection in diabetes.
10. IAP Guidelines on Paediatric Hypertension, 2015 (with updated position statement). Indian Academy of Pediatrics. Weight-based ACEi dosing, BP percentile targets, secondary hypertension workup in children.
11. Key Clinical Trials Referenced:
    • ALLHAT — ALLHAT Officers and Coordinators. JAMA 2002;288(23):2981–2997. Major outcomes in high-risk hypertensive patients randomised to ACEi (lisinopril), CCB (amlodipine), or diuretic (chlorthalidone). n=33,357.
    • ATLAS — Packer M et al. Circulation 1999;100(23):2312–2318. Assessment of Treatment with Lisinopril And Survival. High-dose (32.5–35 mg/day) vs low-dose (2.5–5 mg/day) lisinopril in HF. n=3,164.
    • GISSI-3 — Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico. Lancet 1994;343(8906):1115–1122. Lisinopril (± GTN) in acute MI. n=19,394.
    • ONTARGET — Yusuf S et al. NEJM 2008;358(15):1547–1559. Telmisartan, ramipril, or both in vascular disease. Demonstrated no benefit and increased harm from dual ACEi+ARB therapy.
    • ALTITUDE — Parving HH et al. NEJM 2012;367(23):2204–2213. Aliskiren with ACEi or ARB in T2DM — trial stopped for harm.
    • PARADIGM-HF — McMurray JJ et al. NEJM 2014;371(11):993–1004. Sacubitril/valsartan vs enalapril in HFrEF. Defined the 36-hour ACEi washout protocol before ARNI initiation.
    • CALM — Mogensen CE et al. BMJ 2000;321(7274):1440–1444. Candesartan and lisinopril in T2DM with microalbuminuria.
    • EUCLID — The EUCLID Study Group. Lancet 1997;349(9068):1787–1792. Lisinopril vs placebo in normotensive T1DM with or without microalbuminuria.
    • ESCAPE (Paediatric) — Wühl E et al. NEJM 2009;361(17):1639–1650. Effect of strict BP control and ACE inhibition on progression of CRF in paediatric patients (used ramipril; class extrapolation to lisinopril).
12. KDIGO CKD Guidelines, 2012 (updated 2021). Kidney Disease: Improving Global Outcomes. Sections on: ACEi/ARB use in CKD, proteinuria management, acceptable creatinine rise thresholds.
13. Indian Pharmacopoeia 2022, Volume III. Indian Pharmacopoeia Commission, Ghaziabad. Monograph on Lisinopril Tablets — specifications, identification, assay.
14. LactMed (Drugs and Lactation Database). National Institute of Child Health and Human Development (NICHD), NIH. Lisinopril entry. Accessed June 2025. [Used for lactation safety assessment — no Indian-specific lactation data available.]
15. Drug pricing data verified via:1mg.com, PharmEasy.in, and NPPA (National Pharmaceutical Pricing Authority) drug price database. Prices accessed June 2025.
16. Schrader H et al. Lisinopril in migraine prophylaxis. BMJ 2001;322(7277):19–22. Single RCT, n=60. [Referenced for secondary indication — migraine prophylaxis.]
17. Cooper WO et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. NEJM 2006;354(23):2443–2451. [Referenced for pregnancy teratogenicity data.]

---